Skip to main content
S

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 ASX Professional, scientific and technical activities
Open in API
Filings indexed 110 across all filing types
Latest filing 2026-04-27 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Positive FDA feedback for Amsulostat P2b trial 3 pages 207.1KB
Regulatory Filings Classification · 1% confidence The document is a corporate media release announcing positive FDA feedback and clinical trial milestones, with no financial results, capital raise, board changes, or specific regulatory form filings. It does not fit any specialized category (10-K, IR, ER, M&A, DIRS, etc.) but is a general ASX news announcement. Therefore, it falls into the fallback Regulatory Filings category (RNS).
2026-04-27 English
Continuation of trading halt 1 page 132.9KB
Capital/Financing Update Classification · 1% confidence The document is an ASX announcement dated 28 April 2026 regarding a continuation of a trading halt pending an announcement on a proposed material capital raising. It refers explicitly to Listing Rule 17.1, pending FDA correspondence and planning of a capital raising. Although it is a trading halt request, the core subject is a forthcoming fundraising activity (capital raise). Therefore, it best fits the “Capital/Financing Update” category (CAP).
2026-04-27 English
Trading Halt 2 pages 193.2KB
Regulatory Filings Classification · 1% confidence The document is an ASX market announcement titled “Trading Halt” requested by Syntara Limited under ASX Listing Rule 17.1. It provides regulatory notification about halting trading pending an announcement, with no financial results, dividends, AGM materials, or management changes. It falls under general regulatory filings as a market announcement. Therefore, it is classified as RNS (Regulatory Filings).
2026-04-26 English
Application for quotation of securities - SNT 6 pages 18.4KB
Regulatory Filings
2026-04-12 English
Notification regarding unquoted securities - SNT 6 pages 19.1KB
Regulatory Filings
2026-04-06 English
NWR Virtual Healthcare Conference Presentation 29 pages 3.0MB
Regulatory Filings
2026-03-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.